BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Klygefa (Gefurulimab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Klygefa (Gefurulimab)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06607627-11169@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Klygefa (Gefurulimab): Phase 3 readout est. (NCT06607627)
DESCRIPTION:Klygefa (Gefurulimab)\, phase 3\, Generalized Myasthenia Gravis
 .\nStudy: PK\, PD\, Safety\, and Efficacy Study of Gefurulimab in Pediatri
 c Patients With AChR+ Generalized Myasthenia Gravis\nEstimated primary com
 pletion: 15 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/gefurulimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06607627
URL:https://assetmemo.bio/drug/gefurulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
